Document is current
Any future updates will be listed below
-
Authors
Cussotto, Sofia
Abdennebi, Salma R.
Etting, Isabelle
Denny, Christine A.
Hen, René
Colle, Romain
Corruble, Emmanuelle
Alvarez, Jean-Claude
David, Denis J.
Mendez-David, Indira
-
Funding
Funding for this research was provided by:
Columbia University (2021 Schaefer Award Scholarship)
Agence Nationale de la Recherche (France 2030 program "ANR-11-IDEX-0003,” from the OI HEALTHI of the Université Paris-Saclay)
Agence Nationale de la Recherche (France 2030 program "ANR-11-IDEX-0003,” from the Head Core call from Health and Drug Sciences Graduate school of the Université Paris-Saclay.)
Brain & Behavior Research Foundation (2017 and 2022 Young Investigator Award)
Fondation Pierre Deniker pour la Recherche et la Prévention en Santé Mentale
- License Information
-
More Information
Article History
Received: 24 January 2025
Accepted: 26 January 2026
First Online: 4 February 2026
Competing interests
: I.M.D., D.J.D., and C.A.D. are named on provisional and non-provisional patent applications for the use of novel serotonin type four receptor prophylactics against stress-induced psychiatric disease.
